[{"indications": "Indications\u00a0see under Dose; severe acute ulcerative\r\ncolitis (section 1.5.3); transplantation and graft-versus-host\r\ndisease (section 8.2.2)", "name": "CICLOSPORIN - PREPARATIONS FOR ECZEMA AND PSORIASIS", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "13 Skin", "13.5 Preparations for eczema and psoriasis", "13.5.3 Drugs affecting the immune response"], "cautions": "Cautions\u00a0section 8.2.2Additional cautions in atopic dermatitis and psoriasis\u00a0Contra-indicated  in abnormal\r\nrenal function, uncontrolled hypertension (see also below), infections\r\nnot under control, and malignancy (see also below). Dermatological\r\nand physical examination, including blood pressure and renal function\r\nmeasurements required at least twice before starting. During treatment,\r\nmonitor serum creatinine every 2 weeks for first 3 months then every\r\nmonth; reduce dose by 25\u201350% if serum creatinine increases more than\r\n30% above baseline (even if within normal range) and discontinue if\r\nreduction not successful within 1 month. Discontinue if hypertension\r\ndevelops that cannot be controlled by dose reduction or antihypertensive\r\ntherapy. Avoid excessive exposure to sunlight and avoid use of UVB\r\nor PUVA. In atopic dermatitis, also allow herpes\r\nsimplex infections to clear before starting (if they occur during\r\ntreatment withdraw if severe); Staphylococcus aureus skin infections not absolute contra-indication providing controlled\r\n(but avoid erythromycin unless no other alternative\u2014see\r\nalso interactions: Appendix 1 (ciclosporin)); investigate lymphadenopathy that persists despite improvement\r\nin atopic dermatitis. In psoriasis, also exclude\r\nmalignancies (including those of skin and cervix) before starting\r\n(biopsy any lesions not typical of psoriasis) and treat patients with\r\nmalignant or pre-malignant conditions of skin only after appropriate\r\ntreatment (and if no other option); discontinue if lymphoproliferative\r\ndisorder develops", "side-effects": "Side-effects\u00a0section 8.2.2", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/6000.htm", "doses": ["Short-term treatment (usually for max. 8 weeks but\r\ncan be longer under specialist supervision) of severe atopic dermatitis\r\nwhere conventional therapy ineffective or inappropriate, administered\r\nin accordance with expert advice, by mouth, adult and child over\r\n16 years, initially 2.5\u00a0mg/kg daily in 2 divided doses, if good initial\r\nresponse not achieved within 2 weeks, increase rapidly to max. 5\u00a0mg/kg\r\ndaily; initial dose of 5\u00a0mg/kg daily in 2 divided doses if very severe; child under 16 years see BNF for Children", "Severe psoriasis where conventional therapy ineffective\r\nor inappropriate, administered in accordance with expert advice, by mouth, adult and child over 16 years, initially 2.5\u00a0mg/kg daily in\r\n2 divided doses, increased gradually to max. 5\u00a0mg/kg daily if no improvement\r\nwithin 1 month (discontinue if response still insufficient after 6\r\nweeks); initial dose of 5\u00a0mg/kg daily justified if rapid control required; child under 16 years see BNF for Children", "For preparations and counselling and\r\nfor advice on conversion between the preparations, see section 8.2.2"], "pregnancy": "Pregnancy\u00a0see Immunosuppressant Therapy"}, {"indications": "Indications\u00a0%s\n(From 8.2.2 Corticosteroids and other immunosuppressants: British National Formulary)\nCiclosporin  a calcineurin inhibitor, is a potent immunosuppressant which is virtually non-myelotoxic but markedly nephrotoxic. It has an important role in organ and tissue transplantation, for prevention of graft rejection following bone marrow, kidney, liver, pancreas, heart, lung, and heart-lung transplantation, and for prophylaxis and treatment of graft-versus-host disease., and under Dose; severe acute ulcerative colitis [unlicensed indication]\r\n(section %s\n(From CICLOSPORIN: British National Formulary)\nCICLOSPORIN); rheumatoid arthritis (%s\n(From 10.1.3 Drugs that suppress the rheumatic disease process: British National Formulary)\n10.1.3 Drugs that suppress the rheumatic disease process); atopic\r\ndermatitis and psoriasis (%s\n(From 13.5.3 Drugs affecting the immune response: British National Formulary)\n13.5.3 Drugs affecting the immune response)", "name": "CICLOSPORIN", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "8 Malignant disease and immunosuppression", "8.2 Drugs affecting the immune response", "8.2.2 Corticosteroids and other immunosuppressants", "CICLOSPORIN"], "cautions": "Cautions\u00a0monitor kidney function\u2014dose dependent increase in serum creatinine and urea during first\r\nfew weeks may necessitate dose reduction in transplant patients (exclude\r\nrejection if kidney transplant) or discontinuation in non-transplant\r\npatients; monitor liver function (see Hepatic\r\nImpairment below); monitor blood pressure\u2014discontinue if hypertension develops that cannot be\r\ncontrolled by antihypertensives; hyperuricaemia; monitor serum potassium especially in renal dysfunction (risk of hyperkalaemia); monitor serum magnesium; measure blood\r\nlipids before treatment and after the first month of treatment; use with tacrolimus specifically contra-indicated; for patients other than transplant\r\nrecipients, preferably avoid other immunosuppressants (increased risk\r\nof infection and malignancies, including lymphoma and skin cancer); avoid excessive exposure to UV\r\nlight, including sunlight; interactions: Appendix 1 (ciclosporin)Additional cautions in nephrotic syndrome\u00a0Contra-indicated  in uncontrolled hypertension, uncontrolled infections, and malignancy; in long-term management, perform renal biopsies at yearly intervals", "side-effects": "Side-effects\u00a0anorexia, nausea, vomiting, abdominal pain, diarrhoea,\r\ngingival hyperplasia, hepatic dysfunction, hypertension, tremor, headache,\r\nparaesthesia, fatigue, renal dysfunction (renal structural changes\r\non long-term administration, see also under Cautions), hyperuricaemia,\r\nhyperkalaemia, hypomagnesaemia, hyperlipidaemia, hypercholesterolaemia,\r\nmuscle cramps, myalgia, hypertrichosis; less commonly oedema, weight gain, signs of encephalopathy, anaemia, thrombocytopenia; rarely pancreatitis, motor polyneuropathy, menstrual disturbances,\r\ngynaecomastia, microangiopathic haemolytic anaemia, haemolytic uraemic\r\nsyndrome, hyperglycaemia, muscle weakness, myopathy, visual disturbances\r\nsecondary to benign intracranial hypertension (discontinue); also reported with infusion anaphylaxis", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/31279.htm", "doses": ["Organ transplantation, used alone, adult and child over 3 months 10\u201315\u00a0mg/kg by mouth 4\u201312 hours before transplantation followed by 10\u201315\u00a0mg/kg\r\ndaily for 1\u20132 weeks postoperatively then reduced gradually to 2\u20136\u00a0mg/kg\r\ndaily for maintenance (dose should be adjusted according to blood-ciclosporin concentration and renal function); dose lower\r\nif given concomitantly with other immunosuppressant therapy (e.g. corticosteroids); if necessary one-third corresponding\r\noral dose can be given by intravenous infusion over\r\n2\u20136 hours", "Bone-marrow transplantation, prevention and treatment of graft-versus-host\r\ndisease, adult and child over 3 months 3\u20135\u00a0mg/kg daily by intravenous infusion over 2\u20136 hours from day before transplantation to 2 weeks postoperatively\r\n(or 12.5\u201315\u00a0mg/kg daily by mouth) then 12.5\u00a0mg/kg daily by mouth for 3\u20136 months then tailed off (may take up to a\r\nyear after transplantation)", "Nephrotic syndrome, by mouth, 5\u00a0mg/kg daily in\r\n2 divided doses; child 6\u00a0mg/kg daily\r\nin 2 divided doses; maintenance treatment reduce to lowest effective\r\ndose according to proteinuria and serum creatinine measurements; discontinue\r\nafter 3 months if no improvement in glomerulonephritis or glomerulosclerosis\r\n(after 6 months in membranous glomerulonephritis)", "Patients should be stabilised on a particular brand of oral\r\nciclosporin because switching between formulations without close monitoring\r\nmay lead to clinically important changes in blood-ciclosporin concentration.\r\nPrescribing and dispensing of ciclosporin should be by brand name\r\nto avoid inadvertent switching. If it is necessary to switch a patient\r\nto a different brand of ciclosporin, the patient should be monitored\r\nclosely for changes in blood-ciclosporin concentration, serum creatinine,\r\nblood pressure, and transplant function."], "pregnancy": "Pregnancy\u00a0crosses placenta; see Immunosuppressant Therapy"}, {"indications": "Indications\u00a0%s\n(From 8.2.2 Corticosteroids and other immunosuppressants: British National Formulary)\nCiclosporin  a calcineurin inhibitor, is a potent immunosuppressant which is virtually non-myelotoxic but markedly nephrotoxic. It has an important role in organ and tissue transplantation, for prevention of graft rejection following bone marrow, kidney, liver, pancreas, heart, lung, and heart-lung transplantation, and for prophylaxis and treatment of graft-versus-host disease., and under Dose; severe acute ulcerative colitis [unlicensed indication]\r\n(section %s\n(From CICLOSPORIN: British National Formulary)\nCICLOSPORIN); rheumatoid arthritis (%s\n(From 10.1.3 Drugs that suppress the rheumatic disease process: British National Formulary)\n10.1.3 Drugs that suppress the rheumatic disease process); atopic\r\ndermatitis and psoriasis (%s\n(From 13.5.3 Drugs affecting the immune response: British National Formulary)\n13.5.3 Drugs affecting the immune response)", "name": "CICLOSPORIN - CORTICOSTEROIDS AND OTHER IMMUNOSUPPRESSANTS", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "8 Malignant disease and immunosuppression", "8.2 Drugs affecting the immune response", "8.2.2 Corticosteroids and other immunosuppressants", "CICLOSPORIN"], "cautions": "Cautions\u00a0monitor kidney function\u2014dose dependent increase in serum creatinine and urea during first\r\nfew weeks may necessitate dose reduction in transplant patients (exclude\r\nrejection if kidney transplant) or discontinuation in non-transplant\r\npatients; monitor liver function (see Hepatic\r\nImpairment below); monitor blood pressure\u2014discontinue if hypertension develops that cannot be\r\ncontrolled by antihypertensives; hyperuricaemia; monitor serum potassium especially in renal dysfunction (risk of hyperkalaemia); monitor serum magnesium; measure blood\r\nlipids before treatment and after the first month of treatment; use with tacrolimus specifically contra-indicated; for patients other than transplant\r\nrecipients, preferably avoid other immunosuppressants (increased risk\r\nof infection and malignancies, including lymphoma and skin cancer); avoid excessive exposure to UV\r\nlight, including sunlight; interactions: Appendix 1 (ciclosporin)Additional cautions in nephrotic syndrome\u00a0Contra-indicated  in uncontrolled hypertension, uncontrolled infections, and malignancy; in long-term management, perform renal biopsies at yearly intervals", "side-effects": "Side-effects\u00a0anorexia, nausea, vomiting, abdominal pain, diarrhoea,\r\ngingival hyperplasia, hepatic dysfunction, hypertension, tremor, headache,\r\nparaesthesia, fatigue, renal dysfunction (renal structural changes\r\non long-term administration, see also under Cautions), hyperuricaemia,\r\nhyperkalaemia, hypomagnesaemia, hyperlipidaemia, hypercholesterolaemia,\r\nmuscle cramps, myalgia, hypertrichosis; less commonly oedema, weight gain, signs of encephalopathy, anaemia, thrombocytopenia; rarely pancreatitis, motor polyneuropathy, menstrual disturbances,\r\ngynaecomastia, microangiopathic haemolytic anaemia, haemolytic uraemic\r\nsyndrome, hyperglycaemia, muscle weakness, myopathy, visual disturbances\r\nsecondary to benign intracranial hypertension (discontinue); also reported with infusion anaphylaxis", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/31279.htm", "doses": ["Organ transplantation, used alone, adult and child over 3 months 10\u201315\u00a0mg/kg by mouth 4\u201312 hours before transplantation followed by 10\u201315\u00a0mg/kg\r\ndaily for 1\u20132 weeks postoperatively then reduced gradually to 2\u20136\u00a0mg/kg\r\ndaily for maintenance (dose should be adjusted according to blood-ciclosporin concentration and renal function); dose lower\r\nif given concomitantly with other immunosuppressant therapy (e.g. corticosteroids); if necessary one-third corresponding\r\noral dose can be given by intravenous infusion over\r\n2\u20136 hours", "Bone-marrow transplantation, prevention and treatment of graft-versus-host\r\ndisease, adult and child over 3 months 3\u20135\u00a0mg/kg daily by intravenous infusion over 2\u20136 hours from day before transplantation to 2 weeks postoperatively\r\n(or 12.5\u201315\u00a0mg/kg daily by mouth) then 12.5\u00a0mg/kg daily by mouth for 3\u20136 months then tailed off (may take up to a\r\nyear after transplantation)", "Nephrotic syndrome, by mouth, 5\u00a0mg/kg daily in\r\n2 divided doses; child 6\u00a0mg/kg daily\r\nin 2 divided doses; maintenance treatment reduce to lowest effective\r\ndose according to proteinuria and serum creatinine measurements; discontinue\r\nafter 3 months if no improvement in glomerulonephritis or glomerulosclerosis\r\n(after 6 months in membranous glomerulonephritis)", "Patients should be stabilised on a particular brand of oral\r\nciclosporin because switching between formulations without close monitoring\r\nmay lead to clinically important changes in blood-ciclosporin concentration.\r\nPrescribing and dispensing of ciclosporin should be by brand name\r\nto avoid inadvertent switching. If it is necessary to switch a patient\r\nto a different brand of ciclosporin, the patient should be monitored\r\nclosely for changes in blood-ciclosporin concentration, serum creatinine,\r\nblood pressure, and transplant function."], "pregnancy": "Pregnancy\u00a0crosses placenta; see Immunosuppressant Therapy"}, {"indications": "Indications\u00a0severe acute ulcerative colitis refractory\r\nto corticosteroid treatment [unlicensed indication]; transplantation\r\nand graft-versus-host disease, nephrotic syndrome (section 8.2.2); rheumatoid arthritis (section 10.1.3); atopic dermatitis and psoriasis (section 13.5.3)", "name": "CICLOSPORIN - CHRONIC BOWEL DISORDERS", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "1 Gastro-intestinal system", "1.5 Chronic bowel disorders", "1.5.3 Drugs affecting the immune response", "CICLOSPORIN"], "cautions": "Cautions\u00a0section 8.2.2", "side-effects": "Side-effects\u00a0section 8.2.2", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/201297.htm", "doses": ["By continuous intravenous infusion, adult over 18 years, 2\u00a0mg/kg daily over 24 hours;\r\ndose adjusted according to blood-ciclosporin concentration and response"], "pregnancy": "Pregnancy\u00a0see Immunosuppresant therapy"}, {"indications": "Indications\u00a0severe active rheumatoid arthritis when\r\nconventional second-line therapy inappropriate or ineffective; severe\r\nacute ulcerative colitis [unlicensed indication] (section 1.5.3); graft-versus-host disease (section 8.2.2); atopic\r\ndermatitis and psoriasis (section 13.5.3)", "name": "CICLOSPORIN - DRUGS THAT SUPPRESS THE RHEUMATIC DISEASE PROCESS", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "10 Musculoskeletal and joint diseases", "10.1 Drugs used in rheumatic diseases and gout", "10.1.3 Drugs that suppress the rheumatic disease process", "Drugs affecting the immune response", "CICLOSPORIN"], "cautions": "Cautions\u00a0section 8.2.2Additional cautions in rheumatoid arthritis\u00a0  Contra-indicated  in abnormal\r\nrenal function, uncontrolled hypertension (see also below), uncontrolled infections, and malignancy. Measure serum\r\ncreatinine at least twice before treatment and monitor\r\nevery 2 weeks for first 3 months, then every 4 weeks (or more frequently\r\nif dose increased or concomitant NSAIDs introduced or increased (see\r\nalso  interactions:  Appendix 1\r\n(ciclosporin)), reduce dose if serum creatinine\r\nincreases more than 30% above baseline in more than 1 measurement;\r\nif above 50%, reduce dose by 50% (even if within normal range) and\r\ndiscontinue if reduction not successful within 1 month; monitor blood pressure (discontinue if hypertension\r\ndevelops that cannot be controlled by antihypertensive therapy); monitor hepatic function if concomitant NSAIDs given.", "side-effects": "Side-effects\u00a0section 8.2.2", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/106294.htm", "doses": ["By mouth, administered in accordance with\r\nexpert advice, initially 2.5\u00a0mg/kg daily in 2 divided doses, if necessary\r\nincreased gradually after 6 weeks; max. 4\u00a0mg/kg daily (discontinue\r\nif response insufficient after 3 months); dose adjusted according\r\nto response for maintenance and treatment reviewed after 6 months\r\n(continue only if benefits outweigh risks); child and under 18 years, not recommended ", "For preparations and counselling and\r\nfor advice on conversion between the preparations, see section 8.2.2"], "pregnancy": "Pregnancy\u00a0see section 8.2.2"}]